P
P

Pfizer

Trade Ideas

Traders Sentiment

Technical Summary

Hourly

News

U.S. earnings week ahead

DIARY-U.S. earnings week ahead Jan 27 (Reuters) - Diary of U.S. (.SPX) corporate earnings for the week ahead. ** Please Note - All times given are in U.S. EDT unless otherwise stated ** U.S. EARNINGS Start Date Start Time RIC Company Name Event Name 30-Jan-2023 16:05 WHR Whirlpool Corp Q4 2022 Whirlpool Corp Earnings Release 30-Jan-2023 AMC PFG.O Principal Financial Group Inc Q4 2022 Principal Financial Group Inc Earnings Release 30-Jan-2023 AMC ARE Alexandria Real Estate Equities Inc Q4 2022 Al
A
A
A
C
C
C
D
F
G
G
H
M
M
N
P
P
Q
Q
R
S
A
W
C
E
M
N
T
U
A
A
B
E
I
M
S
T
W
W
Z
A
A
A
A
B
C
C
C
D
F
G
I
O
P
P
S
T

Omicron sub-variant XBB.1.5 accounts for 61.3% of U.S. COVID cases - CDC

UPDATE 1-Omicron sub-variant XBB.1.5 accounts for 61.3% of U.S. COVID cases - CDC Adds background Jan 27 (Reuters) - The Omicron subvariant XBB.1.5 has likely become the dominant variant in the United States, accounting for 61.3% of COVID cases in the week ended Jan. 28, data from the U.S. Centers for Disease Control and Prevention showed on Friday. The subvariant accounted for 49.5% of cases in the week ended Jan.
P

Two COVID vaccine leaders, two different stories

LIVE MARKETS-Two COVID vaccine leaders, two different stories Main U.S. indexes slightly red: Nasdaq off ~0.2% Energy weakest S&P 500 sector; cons disc leads gainers Euro STOXX 600 index off ~0.1% Dollar, crude rise; gold, bitcoin dip U.S. 10-Year Treasury yield rises to ~3.54% Welcome to the home for real-time coverage of markets brought to you by Reuters reporters.
H
P
T
U
G
U
U
U
F
I
S
U
G

EU may pay more for Pfizer COVID shots in return for lower volume

EXCLUSIVE-EU may pay more for Pfizer COVID shots in return for lower volume EU on hook for 400 mln-500 mln Pfizer jabs this year Supply glut now global, but Europe's problem is severe Companies say volume could be cut if higher price paid-source By Maggie Fick Jan 27 (Reuters) - Brussels is discussing with Pfizer PFE.N and BioNTech 22UAy.DE the possibility of reducing the up to 500 million COVID-19 vaccine doses the EU has committed to buy this year in return for a higher price, a source with kn
P

FDA advisers back the same COVID vaccine for initial shots, boosters

UPDATE 1-FDA advisers back the same COVID vaccine for initial shots, boosters Recasts with details, recommendation, quotes from advisory meeting By Michael Erman and Leroy Leo Jan 26 (Reuters) - Advisers to the U.S. Food and Drug Administration on Thursday unanimously voted in favor of targeting the same coronavirus strain for initial COVID-19 vaccine doses and boosters going forward, but some expressed skepticism about whether all Americans need to receive the shots annually.
P

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

We are using cookies to give you the best experience on our website. Read more or change your cookie settings.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.